IDO1 and non-small cell lung carcinoma: Moreover, regarding clinical scenario, these results may be of high relevance, suggesting novel biomarkers to test in early clinical trials, such as Ido-1 activation in MEK inhibitor plus immunotherapy resistant- NSCLC patients enrolled in clinical trials.